Barnes Peter J
National Heart and Lung Institute, Imperial College, School of Medicine, London, United Kingdom.
Ann Ist Super Sanita. 2003;39(4):573-82.
No currently available treatments reduce the progression of chronic obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and lung parenchyma. However, several new treatments now in development for COPD are targeted at the inflammation process. Antagonists of mediators, such as leukotriene B4, interleukin-8, and tumour necrosis factor-alpha and inhibitors of oxidative and nitrative stress are in clinical development. Phosphodiesterase-4 inhibitors are in clinical trials and drugs that inhibit p38 MAP kinase, nuclear factor-kappaB and phosphoinositide-3 kinase-gamma are now in early development. There is also a search for elastase inhibitors to prevent the development of emphysema and drugs that may even reverse the lung destruction.
目前可用的治疗方法均无法减缓慢性阻塞性肺疾病(COPD)的进展,也无法抑制小气道和肺实质的炎症。然而,目前正在研发的几种针对COPD的新疗法均以炎症过程为靶点。白三烯B4、白细胞介素-8和肿瘤坏死因子-α等介质的拮抗剂以及氧化应激和硝化应激抑制剂正处于临床研发阶段。磷酸二酯酶-4抑制剂正在进行临床试验,而抑制p38丝裂原活化蛋白激酶、核因子-κB和磷酸肌醇-3激酶-γ的药物目前正处于早期研发阶段。此外,人们也在寻找弹性蛋白酶抑制剂以预防肺气肿的发展,甚至寻找可能逆转肺部破坏的药物。